| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16072 R66697 |
Christensen (Topiramate) (All indications) (Controls exposed to LTG), 2024 | Low birth weight (<2500 g) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.42 [1.01;1.98] C excluded (control group) |
40/638 395/8,756 | 435 | 638 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16040 R66577 |
Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024 | Low birth weight (<2500 g) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.51 [1.09;2.10] | 40/638 141,442/4,467,848 | 141,482 | 638 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10103 R36815 |
Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 | Weight at birth <2500 g | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.10 [0.74;1.62] C excluded (control group) |
32/477 179/2,916 | 211 | 477 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8613 R28733 |
Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 | Weight at birth <2500 g | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.27 [0.89;1.82] C | 32/477 91,455/1,710,441 | 91,487 | 477 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8599 R28628 |
Hernández-Díaz (Topiramate) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2014 | Low birth weight (< 2500g) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.86 [1.19;2.90] C excluded (control group) |
29/347 74/1,581 | 103 | 347 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8600 R28631 |
Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014 | Low birth weight (< 2500g) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No | 2.22 [1.21;4.08] C | 29/347 18/457 | 47 | 347 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.50 [1.17;1.94] | 233,016 | 1,462 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Topiramate) (All indications) (Controls unexposed, general population; 2: Topiramate) (Controls unexposed, NOS) (Mixed indications; 3: Topiramate) (Mixed indications) (Controls unexposed, disease free;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 8599, 10103, 16072